Published in Blood Weekly, March 16th, 1998
More work is needed, however, to find a dose of valaciclovir that patients can better tolerate, reported Judith E. Feinberg, University of Cincinnati, Cincinnati, Ohio, and colleagues ("A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection," the Journal of Infectious Diseases, 1998;177:48-56).
Cytomegalovirus (CMV) end-organ disease, especially retinitis, commonly occurs as a serious complication of advanced HIV infection.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.